TORONTO, Sept. 29, 2014 /CNW/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, is pleased to announce the appointment of Peter Winkley to Chairman of the Board of Directors of SQI, replacing Claude Ricks. Mr. Ricks will continue to serve as a Director on the Board and will continue to provide leadership to the Company.
"We are very pleased to have Mr. Winkley assume the role of chairman", said Andrew Morris President and CEO. "Peter's years in the industry, independence, and governance experience will be fully utilized in this new role. I would also like to thank Claude for his important contributions as Chairman and for his continued support to the development of SQI."
Mr. Winkley is a CPA, CA and is the Vice-President, Finance and Chief Financial Officer of Algoma Central Corporation and has been a board member of SQI Diagnostics since 2007. Mr. Winkley will continue to serve as chairman of the Audit Committee. Prior to joining Algoma Central, he was V.P., Finance and CFO of Therapure Biopharma Inc., a Mississauga-based biologics contract manufacturer. Peter began his career in the corporate audit practice of Ernst & Young LLP before going on to lead the Corporate Finance function for MDS Inc. Peter has extensive experience with public company financial reporting and governance, treasury, risk management and corporate finance.
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit www.sqidiagnostics.com.
This news release contains certain forward-looking statements, including, without limitation, statements containing the words "will", "expects", "intends" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to general economic and market segment conditions, and international risk and currency exchange, agreements and future agreements to sell our products, the acceleration of our revenue ramp, general economic and market segment conditions. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: SQI Diagnostics Inc.
For further information: Chief Executive Officer, Andrew Morris, 416.674.9500 ext. 229, firstname.lastname@example.org